Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
Open original sourceLoading market dashboard
Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
Open original source